文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

住院COVID-19患者VTE与出血发生率:系统评价与荟萃分析

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-11-17
一句话结论住院COVID-19患者VTE总发生率为17.0%,ICU患者更高(27.9%),筛查诊断率高于临床诊断;出血发生率为7.8%。

该系统评价与荟萃分析检索2020年1月至7月共15个标准及COVID-19专用来源,无语言限制,纳入住院COVID-19患者,采用随机效应模型合并VTE和出血发生率。结果显示VTE总发生率17.0%(95%CI 13.4-20.9),DVT 12.1%,PE 7.1%,出血7.8%,大出血3.9%。亚组分析显示ICU患者VTE发生率27.9%(vs 病房7.1%),筛查诊断33.1%(vs 临床诊断9.8%),接受中/全剂量抗凝者出血发生率21.4%。提示住院COVID-19患者VTE负担高,ICU和筛查人群尤著,抗凝剂量与出血风险相关。

要点

  • 住院COVID-19患者VTE总发生率为17.0%(95%CI 13.4-20.9),ICU患者为27.9%,病房患者为7.1%。
  • 通过筛查诊断的VTE发生率为33.1%,显著高于临床诊断的9.8%。
  • 出血总发生率为7.8%(95%CI 2.6-15.3),大出血为3.9%(95%CI 1.2-7.9)。
  • 接受中/全剂量抗凝的患者出血发生率最高(21.4%),唯一前瞻性评估出血的研究为2.7%。
  • DVT发生率为12.1%(95%CI 8.4-16.4),PE为7.1%(95%CI 5.3-9.1)。

适用人群与场景

  • 住院的COVID-19患者,包括ICU和病房患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,检索15个标准来源和COVID-19专用来源(2020年1月1日至7月31日),无语言限制。
  • 主要终点:VTE合并发生率17.0%(95%CI 13.4-20.9),DVT 12.1%(95%CI 8.4-16.4),PE 7.1%(95%CI 5.3-9.1),出血7.8%(95%CI 2.6-15.3),大出血3.9%(95%CI 1.2-7.9)。
  • 亚组:ICU患者VTE发生率27.9%(vs 病房7.1%),筛查诊断33.1%(vs 临床诊断9.8%),前瞻性研究25.5%(vs 回顾性12.4%)。
  • 出血亚组:接受中/全剂量抗凝者出血发生率21.4%,唯一前瞻性评估出血的研究为2.7%。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析。
  • 局限性:异质性用I2评估,发表偏倚用Begg和Egger检验评估;原文未给出具体等级。

对床旁实践的改变

  • ICU COVID-19患者VTE发生率高(27.9%),应提高对VTE的警惕,筛查可发现更多VTE(33.1% vs 9.8%),但需权衡抗凝相关出血风险(中/全剂量抗凝出血21.4%)。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19).

RESEARCH QUESTION: What is the incidence of VTE and bleeding among hospitalized patients with COVID-19?

METHODS: In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I2 statistic, and publication bias was assessed by using the Begg and Egger tests.

RESULTS: The pooled incidence was 17.0% (95% CI, 13.4-20.9) for VTE, 12.1% (95% CI, 8.4-16.4) for DVT, 7.1% (95% CI, 5.3-9.1) for pulmonary embolism (PE), 7.8% (95% CI, 2.6-15.3) for bleeding, and 3.9% (95% CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1% vs 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs 7.1% in the ward), in prospective studies (25.5% vs 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%).

INTERPRETATION: Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes.

TRIAL REGISTRY: PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Jiménez D, García-Sanchez A, Rali P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33217420. doi:10.1016/j.chest.2020.11.005

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。